Dynavax to Present at Credit Suisse Healthcare Conference
BERKELEY, Calif., Nov 06, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it will present at the Credit Suisse 2008 Healthcare Conference on Wednesday, November 12, 2008 at 3:00 p.m. MST (2:00 p.m. PST) in Phoenix, Arizona. Dino Dina, M.D., President and Chief Executive Officer, will present a corporate overview of Dynavax.
The presentation will be webcast. To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the company's website at http://investors.dynavax.com/events.cfm.
About Dynavax
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of infectious diseases, respiratory diseases and cancer. The company's novel Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary immunostimulatory sequences (ISS), which are short DNA sequences that stimulate the innate immune response. Dynavax's clinical product candidates include: HEPLISAV(TM), a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for hepatitis B; and therapies for cancer and hepatitis C funded by Symphony Dynamo, Inc. The company's preclinical pipeline includes an asthma and COPD drug candidate partnered with AstraZeneca and a Universal Flu vaccine. For more information visit www.dynavax.com.
SOURCE: Dynavax Technologies Corporation
Dynavax Technologies Corporation Amy Figueroa, 510-665-7211 Investor Relations and Corporate Communications afigueroa@dynavax.com
Copyright Business Wire 2008
News Provided by COMTEX